D-0105-2025 Class II Ongoing
FDA drug recall D-0105-2025 was initiated by Rising Pharma Holding, Inc. on Nov 19, 2024 and is designated Class II. Reason for recall: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit The recall status is ongoing. Affected quantity: 209,376 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 11, 2024
- Initiation Date
- Nov 19, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 209,376 bottles
Product description
Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ NDC 57237-017-60
Reason for recall
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
Distribution pattern
Nationwide.
Code information
a) Lot # DT2022023A, DT2022024A, DT2022025A, DT2022026A, DT2022027A, exp. date Nov-24 DT2023001B, DT2023004A, DT2023005A, DT2023006A, exp. date Jan-25
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0105-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026